Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025
A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.
Authors
- Susan L. Hills (ORCID: https://orcid.org/0000-0003-1408-6047)
- Sarah Meyer
- Edwin J. Asturias (ORCID: https://orcid.org/0000-0002-1275-0787)
- Michael M. McNeil (ORCID: https://orcid.org/0000-0003-0713-8312)
- Beth P. Bell
- Lin H. Chen (ORCID: https://orcid.org/0000-0002-5684-8436)
- Melinda Wharton
- Jeffrey Rakickas
- J. Erin Staples (ORCID: https://orcid.org/0000-0002-1446-4071)
- Elaine R. Miller
- Rebekah Sutter (ORCID: https://orcid.org/0009-0006-6695-7421)
Institutions
- Centers for Disease Control and Prevention (US)
- Mount Auburn Hospital (US)
- Harvard University (US)
- University of Washington (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Eurosurveillance
- Published
- 2025-08-14
- DOI
- https://doi.org/10.2807/1560-7917.es.2025.30.32.2500543
- Citations
- 13
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 24.42
Funders
- Centers for Disease Control and Prevention
- National Center for Immunization and Respiratory Diseases